Tumori Journal · 2003 · 14 citations · 27 references
MedicineOncologyPharmacologyMolecular OncologyNeoplasiaNeuro-oncologyAngiogenesisAngiogenesis In CancerCerebral EdemaEdemaHormonal Cancer TherapyVascular SupplyMeningioma PharmacotherapyMicrovascular DensitySomatostatin AnaloguesSomatostatin PharmacologySomatostatin SignalingVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor Signaling
Many tumors, including meningiomas, express somatostatin receptors, suggesting the application of somatostatin analogues for therapy and diagnosis. Sixty percent of meningiomas are associated with perilesional edema, whose development seems to be related to the vascular endothelial growth factor, although it requires an efficient pial blood supply. However, in several neoplastic models, other mediators seem to cooperate with vascular endothelial growth factor in regulating angiogenesis. We evaluated somatostatin receptors (sst2) in relation to the possibility that somatostatin analogues may influence vascular endothelial growth factor production with reduction of edema. Of 35 studied meningiomas, 21 presented peritumoural edema. Vascular endothelial growth factor, microvascular density and pial blood supply were significantly related to the edema (P = 0.0001, P = 0.0001, P = 0.0005). Similarly, a relation was found between sst2 and microvascular density (r = 0.58, P < 0.001) and between sst2 and vascular endothelial growth factor expression (P = 0.03). This suggests that somatostatin analogues may be relevant for the treatment of meningiomas.
27
K. Jin Kim, Bing Li, Jane Winer et al. · Nature · 1993 · 3.6K citations
Medicine, Cancer Biology, Oncology +14
Treatment of the Malignant Carcinoid Syndrome
Larry K. Kvols, Charles G. Moertel, Michael J. O’Connell et al. · New England Journal of Medicine · 1986 · 850 citations
Shi‐Yuan Cheng, Hui Huang, Motoo Nagane et al. · Proceedings of the National Academy of Sciences · 1996 · 347 citations · Full text
Medicine, Cancer Biology, Oncology +16